glp 1 for thyroid issues Microdosing GLP-1 Issues: Who Should Consider It? GLP-1 Receptor Agonists: A Promising
Description
Lancet Diabetes Endocrinol, 7 , 356367
Observational studies have added further evidence
This narrative review summarises the role of incretin mimetics, individually or in combination therapy, in the treatment of MASLD/MASHhighlighting the pathophysiology and mechanisms of action, recent evidence from phase 2 and 3 MASH clinical trials, and clinical benefits
But it can also cause anxiety, or worsen it for those already prone to feelings of nervousness or restlessness
